|
¿ëÇ÷¼º
Çì¸ð±Û·ÎºóÀÌ ÀûÇ÷±¸¿¡¼ À¯¸®ÇÏ¿© Ç÷ÀåÁß¿¡ ³ªÅ¸³ª´Â ¼ºÁú.
myelinated A alpha mechanoreceptor
À¯¼öÃÊ A-¾ËÆÄ ±â°è ¼ö¿ëü, À¯¼öÃÊ A-¾ËÆÄ ±â°è ¼ö¿ë±â
accelerated death phase
°¡¼Ó »ç¸ê±â
acceleration phase
ÃËÁø±â, °¡¼Ó±â
¹Ì»ý¹° ¹è¾ç ½Ã °©Àڱ⠼ºÀåÀÌ Áõ°¡ÇÏ´Â ½Ã±â.
acute phase protein
±Þ¼º±â ´Ü¹éÁú
°¨¿°À̳ª Á¶Á÷ ¼Õ»óÀÌ ÀÖÀ» ¶§ Á¤»óº¸´Ù 2-100¹è Á¤µµ Áõ°¡ÇÏ´Â Ç÷Àå ´Ü¹éÁúÀ» ÃÑĪÇÏ¿© APP¶ó°í ÇÏ¸ç ¼±Ãµ¼º ¸é¿ª¿¡ °ü¿©ÇÑ´Ù.
acute phase reaction
±Þ¼º±â ¹ÝÀÀ
acute phase serum
±Þ¼º º´±â Ç÷û
anal-sadistic phase
Ç×¹®-°¡Çбâ, Ç×¹®-°¡ÇÐ ½Ã±â
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
| 5 beta-cholestane-3 alpha,7 alpha-diol 26-hydroxylase |
<enzyme> Nadp-dependent Registry number: EC 1.14.13.- (26 Jun 1999) |
| 7 alpha-hydroxy-4-cholesten-3-one-12 alpha monooxygenase |
<enzyme> Liver microsomal enzyme active in conversion of cholesterol to cholic acid; introduces a 12 alpha-hydroxyl group into the steroid nucleus of cholesterol Registry number: EC 1.14.99.- Synonym: 7-hco-monooxygenase, hco 12 alpha-hydroxylase (26 Jun 1999) |
| accelerated phase of leukaemia |
Refers to chronic myelogenous leukaemia that is progressing. The number of immature, abnormal white blood cells in the bone marrow and blood is higher than in the chronic phase, but not as high as in the blast phase. (12 Dec 1998) |
| acceleration phase |
<cell biology, cell culture> A period of increasing growth before the log phase in a culture of microbes. After the culture is started on a medium, at first there is no growth (the lag phase) and then the microbes start to gradually grow (acceleration phase) until they reach a constant maximum rate of growth (log phase). (15 Jan 1998) |
| acute-phase protein |
<haematology> These plasma proteins (in addition to fibrinogen) increase 25% or more in response to inflammation and injury are under direct control of interleukin-6 (IL-6) (hepatocyte-stimulating factor). Other proteins which increase are ceruloplasmin, C3 and C4 which increase 50% or more; alpha-1 acid glycoprotein, alpha-1 antitrypsin, haptoglobin and fibrinogen (the major determinant of viscosity 1 ) which increase two- to fourfold; C-reactive protein (CRP) and serum amyloid A which increase several hundred-fold. Despite long-held clinical opinion to the contrary, available data indicate that neither ESR nor measurement of specific acute-phase reactants are useful in excluding underlying infection or inflammation regardless of the pretest probability. These proteins are secreted into the blood in increased or decreased quantities by hepatocytes in response to trauma, inflammation, or disease. They can serve as inhibitors or mediators of the inflammatory processes. Certain acute-phase proteins have been used to diagnose and follow the course of diseases or as tumour markers. See also: amyloid, c-reactive protein, erythrocyte sedimentation rate, viscosity. (25 Jun 1999) |
| acute-phase reaction |
<immunology, rheumatology> Refers to the changes in synthesis of certain proteins within the serum during an inflammatory response, which provides rapid protection for the host against microorganisms via non-specific defense mechanisms. It consists of fever, an increase in inflammatory humoral factors, and an increased synthesis by hepatocytes of a number of proteins or glycoproteins usually found in the plasma; the reaction is mediated by endogenous pyrogens, the hypothalamus, adrenal hormones, and other factors. (12 Jul 2000) |
| anal phase |
In psychoanalytic personality theory, the stage of psychosexual development, occurring when a child is between 1 and 3 years, during which activities, interests, and concerns are centreed around the anal zone. (05 Mar 2000) |
| aqueous phase |
The water portion of a system consisting of two liquid phase's, one mainly water, the other a liquid immiscible with water (e.g., benzene, ether). (05 Mar 2000) |
| blast phase |
Refers to advanced chronic myelogenous leukaemia. In this phase, the number of immature, abnormal white blood cells in the bone marrow and blood is extremely high. Also called blast crisis. (12 Dec 1998) |
| g0 phase |
Phase of the cell cycle where cells exist in a quiescent state. These cells have unduplicated DNA, degraded RNA and protein, and low enzyme activity. The ability to switch between g0 and g1 (and vice versa) determines the post-embryonic cell proliferation rate and is defectively controlled in neoplastic cells. (12 Dec 1998) |
| g1 phase |
<cell biology, molecular biology> The period during interphase in the cell cycle between mitosis and the S phase (when DNA is replicated). Also known as the decision period of the cell, because the cell decides to divide when it enters the s phase. The G stands for gap. (09 Oct 1997) |
| g2 phase |
<cell biology, molecular biology> The period during interphase in the cell cycle between the S phase (when DNA is replicated) and mitosis (when the nucleus, then cell, divides). at this time, the cell checks the accuracy of DNA replication and prepares for mitosis. The G stands for gap. (09 Oct 1997) |
| radial growth phase |
The early pattern of growth of cutaneous malignant melanoma, in which tumour cells spread laterally in the epidermis. (05 Mar 2000) |
| Gap1 phase |
The period of the cell cycle after cell division when there is synthesis of RNA and protein; it may last for a few hours in rapidly growing tissue or a lifetime in non-renewing cells such as nerve cells. Synonym: Gap1 phase, postmitotic phase. (05 Mar 2000) |
| Gap2 phase |
The period in the cell cycle when synthesis of DNA is completed but before mitosis begins. Synonym: Gap2 phase, premitotic phase. (05 Mar 2000) |
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
-
Á¦Ç°¸í
¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
-
Á¦Ç°¸í
¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑ»ýÈÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå |
¼ººÐ/ÇÔ·® |
±¸ºÐ/º¸Çè±Þ¿© |
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå |
¼ººÐ/ÇÔ·® |
±¸ºÐ/º¸Çè±Þ¿© |
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
|